mecasermin
Sign in to saveAlso known as CEP-151, Insulin-like growth factor 1, Somatomedin-C, Mecasermin rinfabate, IGF1, Mechano growth factor, IGF-1, Myotrophin
Mecasermin, sold under the brand name Increlex, also known as recombinant human insulin-like growth factor-1 (rhIGF-1), is a recombinant form of human insulin-like growth factor 1 (IGF-I) which is used in the long-term treatment of growth failure and short stature in children with severe primary IGF-I deficiency, for instance due to growth hormone deficiency or Laron syndrome (growth hormone insensitivity).
Research
103 papers- Mecasermin for primary insulin-like growth factor-1 deficiency.Australian prescriber · 2022
- Mecasermin.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2008
- Mecasermin rinfabate.Drugs of today (Barcelona, Spain : 1998) · 2007
- Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX.Expert opinion on drug metabolism & toxicology · 2008
- PMID 379066592022
via PubMed
Wikidata facts
Show 2 more facts
- defined daily dose
- 2
- NCI Thesaurus ID
- C2262
Sources (2)
via Wikidata · CC0
~1 min read
Article
1 sectionsContents
- References
Mecasermin, sold under the brand name Increlex, also known as recombinant human insulin-like growth factor-1 (rhIGF-1), is a recombinant form of human insulin-like growth factor 1 (IGF-I) which is used in the long-term treatment of growth failure and short stature in children with severe primary IGF-I deficiency, for instance due to growth hormone deficiency or Laron syndrome (growth hormone insensitivity).
Mecasermin has a biological half-life of about 5.8 hours in children with severe primary IGF-1 deficiency.
Available in 11 languages
via Wikidata sitelinks · CC0